Leerink analyst Puneet Souda downgraded Myriad Genetics (MYGN) to Market Perform from Outperform with a $21 price target
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics Settles Shareholder Lawsuits with Reforms
- Myriad announces Prequel Prenatal Screening can be performed at 8 weeks
- Myriad Genetics price target lowered to $21 from $32 at Morgan Stanley
- Myriad Genetics price target lowered to $24 from $34 at Scotiabank
- Myriad Genetics expands access to at-home early fetal sex DNA test